ETFs NovoCure Limited

NVCR

JE00BYSS4X48

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX Other stock markets 03:52:40 2026-05-19 pm EDT			5-day change	1st Jan Change
17.10 ^USD	-2.09%		-6.03%	+33.06%

Apr. 30	NovoCure Limited, Q1 2026 Earnings Call, Apr 30, 2026
Apr. 30	NovoCure Limited Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

ETFs positioned on NovoCure Limited

Name	Varia. Jan 1.	Weight	AuM
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY	+4.97%	0.19%	27 M€
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (UNHEDGED) ETF - JPY	+8.23%	0.01%	426 M€
HSBC MSCI USA QUALITY UCITS ETF - USD	+4.56%	0.01%	326 M€
VANGUARD LIFESTRATEGY 40% EQUITY UCITS ETF - DISTRIBUTING - EUR	+2.66%	0.01%	37 M€
LYXOR MSCI USA ESG BROAD CTB (DR) UCITS ETF - DIST - EUR	-.--%	0%	1,006 M€
VANGUARD LIFESTRATEGY 20% EQUITY UCITS ETF - DISTRIBUTING - EUR	+0.40%	0%	15 M€

1 2

NovoCure Limited is a global oncology company with a proprietary platform technology called Tumor Treating Fields (TTFields), which are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. The Company's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Its Optune Gio is approved by the FDA under the Premarket Approval pathway for the treatment of adult patients with newly diagnosed glioblastoma together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Its Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic non-small cell lung cancer concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen.

Employees

1,605

Sector

Medical Equipment, Supplies & Distribution

More about the company